BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lavine JE, Schwimmer JB, Molleston JP, Scheimann AO, Murray KF, Abrams SH, Rosenthal P, Sanyal AJ, Robuck PR, Brunt EM, Unalp A, Tonascia J; Nonalcoholic Steatohepatitis Clinical Research Network Research Group. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials 2010;31:62-70. [PMID: 19761871 DOI: 10.1016/j.cct.2009.09.001] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
Number Citing Articles
1 Voican CS, Perlemuter G. Insulin resistance and oxidative stress: two therapeutic targets in non-alcoholic steatohepatitis. J Hepatol. 2011;54:388-391. [PMID: 21112115 DOI: 10.1016/j.jhep.2010.07.054] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
2 Kopec KL, Burns D. Nonalcoholic fatty liver disease: a review of the spectrum of disease, diagnosis, and therapy. Nutr Clin Pract. 2011;26:565-576. [PMID: 21947639 DOI: 10.1177/0884533611419668] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 6.8] [Reference Citation Analysis]
3 Andrews DB, Lavine JE. Medical therapy for nonalcoholic fatty liver disease in children and adolescents. Expert Rev Gastroenterol Hepatol 2012;6:1-3. [PMID: 22149573 DOI: 10.1586/egh.11.72] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
4 Vuppalanchi R, Jain AK, Deppe R, Yates K, Comerford M, Masuoka HC, Neuschwander-Tetri BA, Loomba R, Brunt EM, Kleiner DE, Molleston JP, Schwimmer JB, Lavine JE, Tonascia J, Chalasani N. Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2014;12:2121-30.e1-2. [PMID: 24846279 DOI: 10.1016/j.cgh.2014.05.010] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 8.1] [Reference Citation Analysis]
5 Bronsky J, Campoy C, Braegger C; ESPGHAN/ESPEN/ESPR/CSPEN working group on pediatric parenteral nutrition. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Vitamins. Clin Nutr 2018;37:2366-78. [PMID: 30100105 DOI: 10.1016/j.clnu.2018.06.951] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 7.5] [Reference Citation Analysis]
6 Lindbäck SM, Gabbert C, Johnson BL, Smorodinsky E, Sirlin CB, Garcia N, Pardee PE, Kistler KD, Schwimmer JB. Pediatric Nonalcoholic Fatty Liver Disease: A Comprehensive Review. Advances in Pediatrics 2010;57:85-140. [DOI: 10.1016/j.yapd.2010.08.006] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
7 Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology. 2010;52:894-903. [PMID: 20684021 DOI: 10.1002/hep.23759.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Mazzotti A, Caletti MT, Marchignoli F, Forlani G, Marchesini G. Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? Dig Liver Dis 2017;49:235-40. [PMID: 28089623 DOI: 10.1016/j.dld.2016.12.028] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
9 Perito ER, Ajmera V, Bass NM, Rosenthal P, Lavine JE, Schwimmer JB, Yates KP, Diehl AM, Molleston JP, Murray KF, Scheimann A, Gill R, Glidden D, Aouizerat B. Association Between Cytokines and Liver Histology in Children with Nonalcoholic Fatty Liver Disease. Hepatol Commun 2017;1:609-22. [PMID: 29130075 DOI: 10.1002/hep4.1068] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
10 Mazzella N, Ricciardi LM, Mazzotti A, Marchesini G. The Role of Medications for the Management of Patients with NAFLD. Clinics in Liver Disease 2014;18:73-89. [DOI: 10.1016/j.cld.2013.09.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
11 Smith SK, Perito ER. Nonalcoholic Liver Disease in Children and Adolescents. Clin Liver Dis 2018;22:723-33. [PMID: 30266159 DOI: 10.1016/j.cld.2018.07.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
12 Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, Zein CO, Brunt EM, Kleiner DE, McCullough AJ, Sanyal AJ, Diehl AM, Lavine JE, Chalasani N, Kowdley KV; NASH Clinical Research Network. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010;52:913-24. [PMID: 20648476 DOI: 10.1002/hep.23784] [Cited by in Crossref: 290] [Cited by in F6Publishing: 276] [Article Influence: 24.2] [Reference Citation Analysis]
13 Brufani C, Fintini D, Nobili V, Patera PI, Cappa M, Brufani M. Use of metformin in pediatric age. Pediatr Diabetes 2011;12:580-8. [PMID: 21366813 DOI: 10.1111/j.1399-5448.2010.00741.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
14 Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ; NASH CRN. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology. 2010;52:894-903. [PMID: 20684021 DOI: 10.1002/hep.23759] [Cited by in Crossref: 315] [Cited by in F6Publishing: 315] [Article Influence: 26.3] [Reference Citation Analysis]
15 Gawrieh S, Harlow KE, Pike F, Yates KP, Wilson LA, Cummings OW, Rosenberg WM, Chalasani N, Molleston JP. Relationship of Enhanced Liver Fibrosis Score with Pediatric Nonalcoholic Fatty Liver Disease Histology and Response to Vitamin E or Metformin. J Pediatr 2021:S0022-3476(21)00768-X. [PMID: 34400208 DOI: 10.1016/j.jpeds.2021.08.012] [Reference Citation Analysis]
16 St-Jules DE, Watters CA, Nagamori K, King J. The effect of weight loss on pediatric nonalcoholic Fatty liver disease. ISRN Gastroenterol. 2013;2013:398297. [PMID: 23781345 DOI: 10.1155/2013/398297] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Fruci B, Giuliano S, Mazza A, Malaguarnera R, Belfiore A. Nonalcoholic Fatty liver: a possible new target for type 2 diabetes prevention and treatment. Int J Mol Sci. 2013;14:22933-22966. [PMID: 24264040 DOI: 10.3390/ijms141122933] [Cited by in Crossref: 62] [Cited by in F6Publishing: 62] [Article Influence: 6.9] [Reference Citation Analysis]
18 Serviddio G, Bellanti F, Vendemiale G. Free radical biology for medicine: learning from nonalcoholic fatty liver disease. Free Radic Biol Med. 2013;65:952-968. [PMID: 23994574 DOI: 10.1016/j.freeradbiomed.2013.08.174] [Cited by in Crossref: 133] [Cited by in F6Publishing: 120] [Article Influence: 14.8] [Reference Citation Analysis]
19 D'Adamo E, Castorani V, Nobili V. The Liver in Children With Metabolic Syndrome. Front Endocrinol (Lausanne) 2019;10:514. [PMID: 31428049 DOI: 10.3389/fendo.2019.00514] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
20 Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep. 2013;1:57-64. [PMID: 24648894 DOI: 10.3892/br.2012.18] [Cited by in Crossref: 107] [Cited by in F6Publishing: 110] [Article Influence: 10.7] [Reference Citation Analysis]
21 Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 2010;69:211-20. [DOI: 10.1017/s0029665110000030] [Cited by in Crossref: 141] [Cited by in F6Publishing: 68] [Article Influence: 11.8] [Reference Citation Analysis]
22 Molleston JP, Schwimmer JB, Yates KP, Murray KF, Cummings OW, Lavine JE, Brunt EM, Scheimann AO, Unalp-Arida A. Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels. J Pediatr. 2014;164:707-713.e3. [PMID: 24360992 DOI: 10.1016/j.jpeds.2013.10.071] [Cited by in Crossref: 89] [Cited by in F6Publishing: 75] [Article Influence: 9.9] [Reference Citation Analysis]
23 Mameli C, Zuccotti GV, Carnovale C, Galli E, Nannini P, Cervia D, Perrotta C. An update on the assessment and management of metabolic syndrome, a growing medical emergency in paediatric populations. Pharmacol Res 2017;119:99-117. [PMID: 28111263 DOI: 10.1016/j.phrs.2017.01.017] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
24 Bonsembiante L, Targher G, Maffeis C. Non-alcoholic fatty liver disease in obese children and adolescents: a role for nutrition? Eur J Clin Nutr 2021. [PMID: 34006994 DOI: 10.1038/s41430-021-00928-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Alisi A, Locatelli M, Nobili V. Nonalcoholic fatty liver disease in children. Curr Opin Clin Nutr Metab Care 2010;13:397-402. [PMID: 20531177 DOI: 10.1097/MCO.0b013e32833aae84] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
26 Guerrerio AL, Colvin RM, Schwartz AK, Molleston JP, Murray KF, Diehl A, Mohan P, Schwimmer JB, Lavine JE, Torbenson MS. Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr. 2012;95:892-900. [PMID: 22338037 DOI: 10.3945/ajcn.111.020156] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 6.9] [Reference Citation Analysis]
27 Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Ünalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 2011;305:1659-68. [PMID: 21521847 DOI: 10.1001/jama.2011.520] [Cited by in Crossref: 662] [Cited by in F6Publishing: 582] [Article Influence: 60.2] [Reference Citation Analysis]
28 Li Y, Liu L, Wang B, Wang J, Chen D. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep. 2013;1:57-64. [PMID: 24648894 DOI: 10.3892/br.2018.18] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Pala L, Barbaro V, Dicembrini I, Rotella CM. The therapy of insulin resistance in other diseases besides type 2 diabetes. Eat Weight Disord 2014;19:275-83. [PMID: 25069836 DOI: 10.1007/s40519-014-0139-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
30 Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305:1659-1668. [PMID: 21521847 DOI: 10.1001/jama.2011.520.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Reeder SB, Sirlin CB. Quantification of liver fat with magnetic resonance imaging. Magn Reson Imaging Clin N Am. 2010;18:337-357, ix. [PMID: 21094444 DOI: 10.1016/j.mric.2010.08.013] [Cited by in Crossref: 172] [Cited by in F6Publishing: 157] [Article Influence: 15.6] [Reference Citation Analysis]
32 Suzuki A, Abdelmalek MF, Schwimmer JB, Lavine JE, Scheimann AO, Unalp-Arida A, Yates KP, Sanyal AJ, Guy CD, Diehl AM. Association between puberty and features of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2012;10:786-794. [PMID: 22343513 DOI: 10.1016/j.cgh.2012.01.020] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
33 Vadarlis A, Antza C, Bakaloudi DR, Doundoulakis I, Kalopitas G, Samara M, Dardavessis T, Maris T, Chourdakis M. Systematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2021;36:311-9. [PMID: 32810309 DOI: 10.1111/jgh.15221] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
34 Pacifico L, Anania C, Martino F, Poggiogalle E, Chiarelli F, Arca M, Chiesa C. Management of metabolic syndrome in children and adolescents. Nutrition, Metabolism and Cardiovascular Diseases 2011;21:455-66. [DOI: 10.1016/j.numecd.2011.01.011] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 4.8] [Reference Citation Analysis]
35 Schmölz L, Schubert M, Kluge S, Birringer M, Wallert M, Lorkowski S. The Hepatic Fate of Vitamin E. In: Morales-gonzalez JA, editor. Vitamin E in Health and Disease. InTech; 2018. [DOI: 10.5772/intechopen.79445] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
36 Van Wagner LB, Rinella ME. The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis. Therap Adv Gastroenterol. 2011;4:249-263. [PMID: 21765869 DOI: 10.1177/1756283x11403809] [Cited by in Crossref: 49] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
37 Canet MJ, Merrell MD, Hardwick RN, Bataille AM, Campion SN, Ferreira DW, Xanthakos SA, Manautou JE, A-Kader HH, Erickson RP, Cherrington NJ. Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis. Drug Metab Dispos 2015;43:829-35. [PMID: 25788542 DOI: 10.1124/dmd.114.062703] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
38 St-Jules DE, Watters CA, Brunt EM, Wilkens LR, Novotny R, Belt P, Lavine JE. Estimation of fish and ω-3 fatty acid intake in pediatric nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2013;57:627-633. [PMID: 24177784 DOI: 10.1097/mpg.0b013e3182a1df77] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
39 Alkhouri N, Feldstein AE. The TONIC trial: a step forward in treating pediatric nonalcoholic fatty liver disease. Hepatology 2012;55:1292-5. [PMID: 22461076 DOI: 10.1002/hep.24767] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
40 Merrell MD, Cherrington NJ. Drug metabolism alterations in nonalcoholic fatty liver disease.Drug Metab Rev. 2011;43:317-334. [PMID: 21612324 DOI: 10.3109/03602532.2011.577781] [Cited by in Crossref: 103] [Cited by in F6Publishing: 87] [Article Influence: 9.4] [Reference Citation Analysis]
41 Lonardo A, Bellentani S, Ratziu V, Loria P. Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient - death of a dogma from analysis of therapeutic studies? Expert Rev Gastroenterol Hepatol 2011;5:279-89. [PMID: 21476922 DOI: 10.1586/egh.11.19] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 4.2] [Reference Citation Analysis]
42 Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. Exp Diabetes Res. 2012;2012:716404. [PMID: 22194737 DOI: 10.1155/2012/716404] [Cited by in Crossref: 98] [Cited by in F6Publishing: 100] [Article Influence: 8.9] [Reference Citation Analysis]
43 Pacifico L, Nobili V, Anania C, Verdecchia P, Chiesa C. Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol 2011; 17(26): 3082-3091 [PMID: 21912450 DOI: 10.3748/wjg.v17.i26.3082] [Cited by in F6Publishing: 54] [Reference Citation Analysis]
44 Tang A, Tan J, Sun M, Hamilton G, Bydder M, Wolfson T, Gamst AC, Middleton M, Brunt EM, Loomba R, Lavine JE, Schwimmer JB, Sirlin CB. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology. 2013;267:422-431. [PMID: 23382291 DOI: 10.1148/radiol.12120896] [Cited by in Crossref: 259] [Cited by in F6Publishing: 247] [Article Influence: 28.8] [Reference Citation Analysis]
45 Hattar LN, Wilson TA, Tabotabo LA, Smith EO, Abrams SH. Physical activity and nutrition attitudes in obese Hispanic children with non-alcoholic steatohepatitis. World J Gastroenterol 2011; 17(39): 4396-4403 [PMID: 22110265 DOI: 10.3748/wjg.v17.i39.4396] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
46 Mcneice K, Sandberg K. Updates in non-alcoholic fatty liver disease (NAFLD). Current Problems in Pediatric and Adolescent Health Care 2020;50:100844. [DOI: 10.1016/j.cppeds.2020.100844] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Ascher Bartlett JM, Mittal N. Approach to Pediatric Obesity and Nonalcoholic Fatty Liver Disease. Pediatr Ann 2021;50:e474-7. [PMID: 34757877 DOI: 10.3928/19382359-20211019-02] [Reference Citation Analysis]
48 Arab JP, Candia R, Zapata R, Muñoz C, Arancibia JP, Poniachik J, Soza A, Fuster F, Brahm J, Sanhueza E, Contreras J, Cuellar MC, Arrese M, Riquelme A. Management of nonalcoholic fatty liver disease: An evidence-based clinical practice review. World J Gastroenterol 2014; 20(34): 12182-12201 [PMID: 25232252 DOI: 10.3748/wjg.v20.i34.12182] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
49 Ng K, Stoll B, Chacko S, Saenz de Pipaon M, Lauridsen C, Gray M, Squires EJ, Marini J, Zamora IJ, Olutoye OO, Burrin DG. Vitamin E in New-Generation Lipid Emulsions Protects Against Parenteral Nutrition-Associated Liver Disease in Parenteral Nutrition-Fed Preterm Pigs. JPEN J Parenter Enteral Nutr 2016;40:656-71. [PMID: 25596209 DOI: 10.1177/0148607114567900] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.7] [Reference Citation Analysis]
50 Alisi A, Nobili V. Nonalcoholic fatty liver disease: Targeted therapy in children--what is the right way? Nat Rev Gastroenterol Hepatol 2011;8:425-6. [PMID: 21750513 DOI: 10.1038/nrgastro.2011.117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
51 Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, Mouzaki M, Sathya P, Schwimmer JB, Sundaram SS, Xanthakos SA. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr 2017;64:319-34. [PMID: 28107283 DOI: 10.1097/MPG.0000000000001482] [Cited by in Crossref: 306] [Cited by in F6Publishing: 133] [Article Influence: 76.5] [Reference Citation Analysis]
52 Patton HM, Yates K, Unalp-Arida A, Behling CA, Huang TT, Rosenthal P, Sanyal AJ, Schwimmer JB, Lavine JE. Association between metabolic syndrome and liver histology among children with nonalcoholic Fatty liver disease. Am J Gastroenterol. 2010;105:2093-2102. [PMID: 20372110 DOI: 10.1038/ajg.2010.152] [Cited by in Crossref: 115] [Cited by in F6Publishing: 106] [Article Influence: 9.6] [Reference Citation Analysis]
53 Corey KE, Vuppalanchi R, Vos M, Kohli R, Molleston JP, Wilson L, Unalp-Arida A, Cummings OW, Lavine JE, Chalasani N. Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2015;60:360-367. [PMID: 25714579 DOI: 10.1097/mpg.0000000000000584] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]